Our findings reveal a novel STT3A-FCN3-β-catenin signaling axis that promotes HCC progression by modulating Treg-mediated immunosuppression, thereby providing crucial insights into HCC immune evasion mechanisms and potential therapeutic targets. This evidence concerns the gene STT3A and hepatocellular carcinoma.